Royal Bank of Canada Has $31.92 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Royal Bank of Canada raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 442,769 shares of the medical equipment provider's stock after purchasing an additional 51,898 shares during the period. Royal Bank of Canada owned 0.20% of Hologic worth $31,919,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Hologic in the 4th quarter valued at about $133,414,000. Boston Partners grew its stake in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Champlain Investment Partners LLC bought a new position in shares of Hologic during the 4th quarter worth approximately $79,291,000. Northern Trust Corp grew its stake in shares of Hologic by 26.9% during the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after acquiring an additional 668,086 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after buying an additional 572,187 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

Shares of HOLX stock opened at $54.48 on Friday. The business's 50-day moving average price is $58.32 and its 200-day moving average price is $66.78. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The firm has a market capitalization of $12.14 billion, a price-to-earnings ratio of 17.19, a PEG ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm's quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.03 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on HOLX shares. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Raymond James reissued an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Citigroup decreased their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Argus cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.